Sanfilippo Syndrome Patients, Drug Developers At Odds With US FDA Guidance

 
• By Sue Sutter
Barrier
An FDA draft guidance has become a barrier to developing drugs for MPS III, advocates and sponsors say. • Source: Shutterstock

More from Approval Standards

More from Pathways & Standards